Followers | 31 |
Posts | 2649 |
Boards Moderated | 0 |
Alias Born | 10/28/2013 |
Saturday, November 14, 2015 2:23:08 PM
If you add Feuerstein's widely publicised and circulated "Thesis" (his BA Thesis?) which states that emerging biotechs with less than $300M market caps are doomed to fail, then these men are not just controlling how easy life will be for emerging biotechs, but whether they will survive at all. On the verge of collapse, these companies either get aquired on the cheap by the big pharma's in these men's hedge funds / associates' hedge funds, or they die and their threat of competition is gone.
Anavex is absolutely a major threat to Axon. Just as NWBO is a major threat to Celldex, one of Jim Cramer's darlings. If you examine Cramer's recommendations and the holdings in his associate's hedge funds, as well as the holding's in Martin Shrikeli's hedge fund, I am willing to bet that Axon is a major holding.
Two or three men, tightly connected. Feuerstein's first job in the Biotech Arena was working for Cramer as a "Biotech Reporter". Martin Shkreli's first job period, was working for four years as an intern at Cramer's hedge fund. They both learned from the master. The master of what? According to Cramer, among other things, the master of stock price manipulation via circulation of damaging, false rumors, when it serves the hedge fund's purposes. Cramer is an admitted big time securities crook who managed to escape prison and land a job as the most widely watched stock advisor on the planet, because he has connections to people in positions of power.
Anavex was getting overhyped, and whoever drove the Agora Financial article should be fired or shot... but the fact is, there is no real reason to believe that Anavex had anything to do with that. As a long investor, I have watched CEO Missling in his interviews and conference webcasts, and I have consistently witnessed him understate expectations of efficacy. His standard line is that we just have to go through the trials and wait and see.
That said, I have to back off from saying how impressed I am with the recently circulated chart showing impressive efficacy for Anavex 2-73 Plus (75% Plus, 25% w/o adjunct generic) through 16 or 18 weeks. I don't understand the chart. My knee jerk was to be very impressed, and I put on the back burner trying to understand the textual explanations under the chart... but after three brief tries, I admit, I have no idea what that chart is showing. It is very impressive, but what is it? It's frankendata. A mix of data from different tests? I don't think it is in the best interest of the company to circulate an impressive looking chart that is so confusing. But I don't think Anavex did cirulate the chart. I am confused about all that. Looks like a technical individual put that together, and it might be very meaningful, but I shouldn't say that it is, because, I don't understand it.
The chart is very important because the criticism that 5 week data is not super meaningfull is a legitimate criticism. It is wonderful that the 5 week data looks good, but the critics are right that 10 cups of coffee, or maybe 3, might have good results at 5 weeks. But not at 18 weeks. There would be burnout by 18 weeks. Certainly not a consistent, continuing increase in efficacy, as that frankenchart showed. So... I agree that the 24 week data (or 26) is super important, and that the proper SP/cap is difficult to determine until then, but I don't agree that it is Cramer, Feuerstein, and Skreli's right to set that $Value using their tremendous reach and outright lies. That is flatly illegal and should be dealt with as such. Those three people people are fkng nobody!
Recent AVXL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM